The north American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors

Jonathan R. Strosberg, Thorvardur R. Halfdanarson, Andrew M. Bellizzi, Jennifer A. Chan, Joseph S. Dillon, Anthony P. Heaney, Pamela L. Kunz, Thomas M. O'Dorisio, Riad Salem, Eva Segelov, James R. Howe, Rodney Pommier, Kari Brendtro, Mohammad A. Bashir, Simron Singh, Michael C. Soulen, Laura Tang, Jerome S. Zacks, James C. Yao, Emily K. Bergsland

    Research output: Contribution to journalArticle

    66 Citations (Scopus)

    Abstract

    There have been significant developments in diagnostic and therapeutic options for patients with neuroendocrine tumors (NETs). Key phase 3 studies include the CLARINET trial, which evaluated lanreotide in patients with nonfunctioning enteropancreatic NETs; the RADIANT-2 and RADIANT-4 studies, which evaluated everolimus in functioning and nonfunctioning NETs of the gastrointestinal tract and lungs; the TELESTAR study, which evaluated telotristat ethyl in patientswith refractory carcinoid syndrome; and the NETTER-1 trial, which evaluated 177Lu-DOTATATE in NETs of the small intestine and proximal colon (midgut). Based on these and other advances, the North American Neuroendocrine Tumor Society convened a multidisciplinary panel of experts with the goal of updating consensus-based guidelines for evaluation and treatment of midgut NETs. The medical aspects of these guidelines (focusing on systemic treatment, nonsurgical liver-directed therapy, and postoperative surveillance) are summarized in this article. Surgical guidelines are described in a companion article.

    Original languageEnglish (US)
    Pages (from-to)707-714
    Number of pages8
    JournalPancreas
    Volume46
    Issue number6
    DOIs
    StatePublished - 2017

    Fingerprint

    Neuroendocrine Tumors
    Guidelines
    Carcinoid Tumor
    Therapeutics
    Small Intestine
    Gastrointestinal Tract
    Colon
    Lung
    Liver

    Keywords

    • Medical management
    • Midgut NETs
    • NANETS
    • Neuroendocrine tumor

    ASJC Scopus subject areas

    • Internal Medicine
    • Endocrinology, Diabetes and Metabolism
    • Hepatology
    • Endocrinology

    Cite this

    Strosberg, J. R., Halfdanarson, T. R., Bellizzi, A. M., Chan, J. A., Dillon, J. S., Heaney, A. P., ... Bergsland, E. K. (2017). The north American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas, 46(6), 707-714. https://doi.org/10.1097/MPA.0000000000000850

    The north American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. / Strosberg, Jonathan R.; Halfdanarson, Thorvardur R.; Bellizzi, Andrew M.; Chan, Jennifer A.; Dillon, Joseph S.; Heaney, Anthony P.; Kunz, Pamela L.; O'Dorisio, Thomas M.; Salem, Riad; Segelov, Eva; Howe, James R.; Pommier, Rodney; Brendtro, Kari; Bashir, Mohammad A.; Singh, Simron; Soulen, Michael C.; Tang, Laura; Zacks, Jerome S.; Yao, James C.; Bergsland, Emily K.

    In: Pancreas, Vol. 46, No. 6, 2017, p. 707-714.

    Research output: Contribution to journalArticle

    Strosberg, JR, Halfdanarson, TR, Bellizzi, AM, Chan, JA, Dillon, JS, Heaney, AP, Kunz, PL, O'Dorisio, TM, Salem, R, Segelov, E, Howe, JR, Pommier, R, Brendtro, K, Bashir, MA, Singh, S, Soulen, MC, Tang, L, Zacks, JS, Yao, JC & Bergsland, EK 2017, 'The north American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors', Pancreas, vol. 46, no. 6, pp. 707-714. https://doi.org/10.1097/MPA.0000000000000850
    Strosberg, Jonathan R. ; Halfdanarson, Thorvardur R. ; Bellizzi, Andrew M. ; Chan, Jennifer A. ; Dillon, Joseph S. ; Heaney, Anthony P. ; Kunz, Pamela L. ; O'Dorisio, Thomas M. ; Salem, Riad ; Segelov, Eva ; Howe, James R. ; Pommier, Rodney ; Brendtro, Kari ; Bashir, Mohammad A. ; Singh, Simron ; Soulen, Michael C. ; Tang, Laura ; Zacks, Jerome S. ; Yao, James C. ; Bergsland, Emily K. / The north American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. In: Pancreas. 2017 ; Vol. 46, No. 6. pp. 707-714.
    @article{0704d2489eb74c96a14bce77c75cdc36,
    title = "The north American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors",
    abstract = "There have been significant developments in diagnostic and therapeutic options for patients with neuroendocrine tumors (NETs). Key phase 3 studies include the CLARINET trial, which evaluated lanreotide in patients with nonfunctioning enteropancreatic NETs; the RADIANT-2 and RADIANT-4 studies, which evaluated everolimus in functioning and nonfunctioning NETs of the gastrointestinal tract and lungs; the TELESTAR study, which evaluated telotristat ethyl in patientswith refractory carcinoid syndrome; and the NETTER-1 trial, which evaluated 177Lu-DOTATATE in NETs of the small intestine and proximal colon (midgut). Based on these and other advances, the North American Neuroendocrine Tumor Society convened a multidisciplinary panel of experts with the goal of updating consensus-based guidelines for evaluation and treatment of midgut NETs. The medical aspects of these guidelines (focusing on systemic treatment, nonsurgical liver-directed therapy, and postoperative surveillance) are summarized in this article. Surgical guidelines are described in a companion article.",
    keywords = "Medical management, Midgut NETs, NANETS, Neuroendocrine tumor",
    author = "Strosberg, {Jonathan R.} and Halfdanarson, {Thorvardur R.} and Bellizzi, {Andrew M.} and Chan, {Jennifer A.} and Dillon, {Joseph S.} and Heaney, {Anthony P.} and Kunz, {Pamela L.} and O'Dorisio, {Thomas M.} and Riad Salem and Eva Segelov and Howe, {James R.} and Rodney Pommier and Kari Brendtro and Bashir, {Mohammad A.} and Simron Singh and Soulen, {Michael C.} and Laura Tang and Zacks, {Jerome S.} and Yao, {James C.} and Bergsland, {Emily K.}",
    year = "2017",
    doi = "10.1097/MPA.0000000000000850",
    language = "English (US)",
    volume = "46",
    pages = "707--714",
    journal = "Pancreas",
    issn = "0885-3177",
    publisher = "Lippincott Williams and Wilkins",
    number = "6",

    }

    TY - JOUR

    T1 - The north American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors

    AU - Strosberg, Jonathan R.

    AU - Halfdanarson, Thorvardur R.

    AU - Bellizzi, Andrew M.

    AU - Chan, Jennifer A.

    AU - Dillon, Joseph S.

    AU - Heaney, Anthony P.

    AU - Kunz, Pamela L.

    AU - O'Dorisio, Thomas M.

    AU - Salem, Riad

    AU - Segelov, Eva

    AU - Howe, James R.

    AU - Pommier, Rodney

    AU - Brendtro, Kari

    AU - Bashir, Mohammad A.

    AU - Singh, Simron

    AU - Soulen, Michael C.

    AU - Tang, Laura

    AU - Zacks, Jerome S.

    AU - Yao, James C.

    AU - Bergsland, Emily K.

    PY - 2017

    Y1 - 2017

    N2 - There have been significant developments in diagnostic and therapeutic options for patients with neuroendocrine tumors (NETs). Key phase 3 studies include the CLARINET trial, which evaluated lanreotide in patients with nonfunctioning enteropancreatic NETs; the RADIANT-2 and RADIANT-4 studies, which evaluated everolimus in functioning and nonfunctioning NETs of the gastrointestinal tract and lungs; the TELESTAR study, which evaluated telotristat ethyl in patientswith refractory carcinoid syndrome; and the NETTER-1 trial, which evaluated 177Lu-DOTATATE in NETs of the small intestine and proximal colon (midgut). Based on these and other advances, the North American Neuroendocrine Tumor Society convened a multidisciplinary panel of experts with the goal of updating consensus-based guidelines for evaluation and treatment of midgut NETs. The medical aspects of these guidelines (focusing on systemic treatment, nonsurgical liver-directed therapy, and postoperative surveillance) are summarized in this article. Surgical guidelines are described in a companion article.

    AB - There have been significant developments in diagnostic and therapeutic options for patients with neuroendocrine tumors (NETs). Key phase 3 studies include the CLARINET trial, which evaluated lanreotide in patients with nonfunctioning enteropancreatic NETs; the RADIANT-2 and RADIANT-4 studies, which evaluated everolimus in functioning and nonfunctioning NETs of the gastrointestinal tract and lungs; the TELESTAR study, which evaluated telotristat ethyl in patientswith refractory carcinoid syndrome; and the NETTER-1 trial, which evaluated 177Lu-DOTATATE in NETs of the small intestine and proximal colon (midgut). Based on these and other advances, the North American Neuroendocrine Tumor Society convened a multidisciplinary panel of experts with the goal of updating consensus-based guidelines for evaluation and treatment of midgut NETs. The medical aspects of these guidelines (focusing on systemic treatment, nonsurgical liver-directed therapy, and postoperative surveillance) are summarized in this article. Surgical guidelines are described in a companion article.

    KW - Medical management

    KW - Midgut NETs

    KW - NANETS

    KW - Neuroendocrine tumor

    UR - http://www.scopus.com/inward/record.url?scp=85020887054&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85020887054&partnerID=8YFLogxK

    U2 - 10.1097/MPA.0000000000000850

    DO - 10.1097/MPA.0000000000000850

    M3 - Article

    C2 - 28609356

    AN - SCOPUS:85020887054

    VL - 46

    SP - 707

    EP - 714

    JO - Pancreas

    JF - Pancreas

    SN - 0885-3177

    IS - 6

    ER -